title: Premenstrual Syndrome and Premenstrual Dysphoric Disorder.
abstract: Premenstrual disorders affect up to 12% of women. The subspecialties of psychiatry and gynecology have developed overlapping but distinct diagnoses that qualify as a premenstrual disorder; these include premenstrual syndrome and premenstrual dysphoric disorder. These conditions encompass psychological and physical symptoms that cause significant impairment during the luteal phase of the menstrual cycle, but resolve shortly after menstruation. Patientdirected prospective recording of symptoms is helpful to establish the cyclical nature of symptoms that differentiate premenstrual syndrome and premenstrual dysphoric disorder from other psychiatric and physical disorders. Physicians should tailor therapy to achieve the greatest functional improvement possible for their patients. Select serotonergic antidepressants are first-line treatments. They can be used continuously or only during the luteal phase. Oral contraceptives and calcium supplements may also be used. There is insufficient evidence to recommend treatment with vitamin D, herbal remedies, or acupuncture, but there are data to suggest benefit from cognitive behavior therapy.
authors.affiliation: Medical College of Wisconsin, Milwaukee, WI, USA.
authors.forename: Sabrina
authors.initials: S
authors.lastname: Hofmeister
authors.affiliation: Medical College of Wisconsin, Milwaukee, WI, USA.
authors.forename: Seth
authors.initials: S
authors.lastname: Bodden
mesh_terms: D002118:Calcium / Q000627:therapeutic use; D015928:Cognitive Behavioral Therapy; D003278:Contraceptives, Oral, Hormonal / Q000627:therapeutic use; D019587:Dietary Supplements; D005260:Female; D006801:Humans; D065446:Premenstrual Dysphoric Disorder / Q000175:diagnosis* / Q000628:therapy; D011293:Premenstrual Syndrome / Q000175:diagnosis* / Q000628:therapy; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use
chemical_list: D002118:Calcium; D003278:Contraceptives, Oral, Hormonal; D017367:Selective Serotonin Reuptake Inhibitors